Skip to main content
. Author manuscript; available in PMC: 2009 Jul 22.
Published in final edited form as: Am J Psychiatry. 2008 Jun 2;165(7):844–854. doi: 10.1176/appi.ajp.2008.07111779

Table 3.

Change on clinical symptom measures between baseline and treatment week 12. ^

Olanzapine (N = 40) Quetiapine (N = 31) Risperidone (N = 33) Placebo (N = 47)

ADCS-ADL total score, mean change (SD) −6.1 (8.2) * −1.0 (7.7) −1.1 (8.8) 0.5 (8.4)
ADAS-Cog total score, mean change (SD) 0.7 (6.1) 0.8 (6.9) 1.7 (5.2) 1.3 (5.7)
MMSE score, mean change (SD) −0.1 (3.7) −0.8 (3.8) −0.8 (3.2) −0.7 (2.7)
ADRQL total score, mean change (SD) 6.4 (12.6) 6.7 (11.7) 2.1 (12.1) 4.1 (15.8)
Caregiver Activity Survey, mean change in hours (SD) 0.2 (4.8) −0.7 (4.3) −1.1 (4.7) −0.6 (4.1)
^

Mean change score for those patients taking the assigned phase 1 medication at week 12 are shown.

For ADCS-ADL, MMSE, and ADRQL, a change score >0 reflects clinical improvement. For ADAS-Cog and Caregiver Activity Survey, a change score <0 reflects clinical improvement.

*

p<.001, pairwise comparison vs. placebo; ANCOVA model with adjustment for pooled site and baseline score.

HHS Vulnerability Disclosure